Nadia El Mouaddin
Overview
Explore the profile of Nadia El Mouaddin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
18
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee A, Davido B, Beck E, Demont C, Joshi K, Kohli M, et al.
Hum Vaccin Immunother
. 2024 Nov;
20(1):2423474.
PMID: 39540209
An evaluation was conducted to predict the economic and clinical burden of vaccinating all immunocompromised (IC) individuals aged ≥30 years with mRNA-1273 variant-adapted COVID-19 vaccines versus BNT162b2 variant-adapted vaccines in...
2.
Rodrigues M, Eberst L, Follana P, Gauthier L, Jacquemin V, Tessier C, et al.
Bull Cancer
. 2023 Sep;
110(10):1041-1050.
PMID: 37659907
Introduction: In October 2020, the French Health Authority granted early access outside of the clinical trial setting for dostarlimab, a programmed death-1 inhibitor. Dostarlimab was approved by the European Medicines...
3.
Morais E, El Mouaddin N, Schuurman S, De A
Vaccine
. 2021 Aug;
39(39):5461-5473.
PMID: 34452775
Introduction: Head and neck cancers (HNC) accounted for over 450,000 deaths and 900,000 cases in 2018 worldwide. Of those, 38,000 cases were attributable to human papillomavirus (HPV). HNC is two...
4.
Majed L, Bresse X, El Mouaddin N, Schmidt A, Daniels V, Pavelyev A, et al.
Vaccine
. 2020 Dec;
39(2):438-446.
PMID: 33261895
Objectives: In France, 9-valent HPV vaccination is recommended routinely for 11-14-years-old girls and as catch-up for 15-19-years-old girls. Recently, recommendation for gender-neutral vaccination (GNV) has been approved. The objectives of...
5.
Kind A, Pavelyev A, Kothari S, El Mouaddin N, Schmidt A, Morais E, et al.
BMC Public Health
. 2020 May;
20(1):671.
PMID: 32398057
Background: An infection with high-risk human papillomavirus (HPV) is the obligatory aetiological factor for the development of cervical cancer. In Switzerland, the prevention strategy for cervical cancer is based on...